{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T08:05:19Z","timestamp":1794989119805,"version":"4.9.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["2022YFS0315"],"award-info":[{"award-number":["2022YFS0315"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["2022NSFSC1432"],"award-info":[{"award-number":["2022NSFSC1432"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M732455"],"award-info":[{"award-number":["2023M732455"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Peripheral glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) are sensitive markers of neuroinflammation and neuronal damage. Previous studies with highly selected participants have shown that peripheral GFAP and NfL levels are elevated in the pre-clinical phase of Alzheimer\u2019s disease (AD) and dementia. However, the predictive value of GFAP and NfL for dementia requires more evidence from population-based cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a prospective cohort study to evaluate UK Biobank participants enrolled from 2006 to 2010 using plasma GFAP and NfL measurements measured by Olink Target Platform and prospectively followed up for dementia diagnosis. Primary outcome was the risk of clinical diagnosed dementia. Secondary outcomes were cognition. Linear regression was used to assess the associations between peripheral GFAP and NfL with cognition. Cox proportional hazard models with cross-validations were used to estimate associations between elevated GFAP and NfL with risk of dementia. All models were adjusted for covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A subsample of 48,542 participants in the UK Biobank with peripheral GFAP and NfL measurements were evaluated. With an average follow-up of 13.18\u2009\u00b1\u20092.42\u00a0years, 1312 new all-cause dementia cases were identified. Peripheral GFAP and NfL increased up to 15\u00a0years before dementia diagnosis was made. After strictly adjusting for confounders, increment in NfL was found to be associated with decreased numeric memory and prolonged reaction time. A greater annualized rate of change in GFAP was significantly associated with faster global cognitive decline. Elevation of GFAP (hazard ratio (HR) ranges from 2.25 to 3.15) and NfL (HR ranges from 1.98 to 4.23) increased the risk for several types of dementia. GFAP and NfL significantly improved the predictive values for dementia using previous models (area under the curve (AUC) ranges from 0.80 to 0.89, C-index ranges from 0.86 to 0.91). The AD genetic risk score and number of APOE*E4 alleles strongly correlated with GFAP and NfL levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results suggest that peripheral GFAP and NfL are potential biomarkers for the early diagnosis of dementia. In addition, anti-inflammatory therapies in the initial stages of dementia may have potential benefits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-024-03418-8","type":"journal-article","created":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T20:01:53Z","timestamp":1715544113000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":128,"title":["Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank"],"prefix":"10.1186","volume":"22","author":[{"given":"Xiaofei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongren","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,13]]},"reference":[{"key":"3418_CR1","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/joim.13227","volume":"289","author":"I Lisko","year":"2021","unstructured":"Lisko I, Kulmala J, Annetorp M, Ngandu T, Mangialasche F, Kivipelto M. How can dementia and disability be prevented in older adults: where are we today and where are we going? J Intern Med. 2021;289:807\u201330.","journal-title":"J Intern Med"},{"key":"3418_CR2","unstructured":"GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7:e105\u201325."},{"key":"3418_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"3418_CR4","unstructured":"NIA-AA Workgroup. NIA-AA revised diagnostic criteria: a biological definition of Alzheimer\u2019s disease. Accessed 19 Sep 2023."},{"key":"3418_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001694","volume":"20","author":"C Haass","year":"2022","unstructured":"Haass C, Selkoe D. If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline? PLoS Biol. 2022;20: e3001694.","journal-title":"PLoS Biol"},{"key":"3418_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101492","volume":"72","author":"L Feng","year":"2021","unstructured":"Feng L, Li J, Zhang R. Current research status of blood biomarkers in Alzheimer\u2019s disease: diagnosis and prognosis. Ageing Res Rev. 2021;72: 101492.","journal-title":"Ageing Res Rev"},{"key":"3418_CR7","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","volume":"20","author":"B Dubois","year":"2021","unstructured":"Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, et al. Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the International Working Group. Lancet Neurol. 2021;20:484\u201396.","journal-title":"Lancet Neurol"},{"key":"3418_CR8","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S1474-4422(21)00077-6","volume":"20","author":"WJ Jagust","year":"2021","unstructured":"Jagust WJ. The changing definition of Alzheimer\u2019s disease. Lancet Neurol. 2021;20:414\u20135.","journal-title":"Lancet Neurol"},{"key":"3418_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/13543784.2017.1323868","volume":"26","author":"D Mehta","year":"2017","unstructured":"Mehta D, Jackson R, Paul G, Shi J, Sabbagh M. Why do trials for Alzheimer\u2019s disease drugs keep failing? A discontinued drug perspective for 2010\u20132015. Expert Opin Investig Drugs. 2017;26:735\u20139.","journal-title":"Expert Opin Investig Drugs"},{"key":"3418_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jalz.2015.12.003","volume":"12","author":"S Gauthier","year":"2016","unstructured":"Gauthier S, Albert M, Fox N, Goedert M, Kivipelto M, Mestre-Ferrandiz J, et al. Why has therapy development for dementia failed in the last two decades? Alzheimers Dement. 2016;12:60\u20134.","journal-title":"Alzheimers Dement"},{"key":"3418_CR11","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/15622975.2019.1696473","volume":"21","author":"S Kasper","year":"2020","unstructured":"Kasper S, Bancher C, Eckert A, F\u00f6rstl H, Fr\u00f6lich L, Hort J, et al. Management of mild cognitive impairment (MCI): the need for national and international guidelines. World J Biol Psychiatry. 2020;21:579\u201394.","journal-title":"World J Biol Psychiatry"},{"key":"3418_CR12","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet AL, Mil\u00e0-Alom\u00e0 M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer Disease Continuum. JAMA Neurol. 2021;78:1471.","journal-title":"JAMA Neurol"},{"key":"3418_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02505-2","author":"WK Self","year":"2023","unstructured":"Self WK, Holtzman DM. Emerging diagnostics and therapeutics for Alzheimer disease. Nat Med. 2023. https:\/\/doi.org\/10.1038\/s41591-023-02505-2.","journal-title":"Nat Med"},{"key":"3418_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, et al. Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol. 2022;21:66\u201377.","journal-title":"Lancet Neurol"},{"key":"3418_CR15","doi-asserted-by":"crossref","unstructured":"Gaur A, Rivet L, Mah E, Bawa KK, Gallagher D, Herrmann N, et al. Novel fluid biomarkers for mild cognitive impairment: a systematic review and meta-analysis. Ageing Research Reviews. 2023;:102046.","DOI":"10.1016\/j.arr.2023.102046"},{"key":"3418_CR16","doi-asserted-by":"crossref","unstructured":"Cronj\u00e9 HT, Liu X, Odden MC, Moseholm KF, Seshadri S, Satizabal CL, et al. Serum NfL and GFAP are associated with incident dementia and dementia mortality in older adults: the cardiovascular health study. Alzheimer\u2019s & Dementia. 2023;:alz.13367.","DOI":"10.1002\/alz.079666"},{"key":"3418_CR17","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41582-023-00792-4","volume":"19","author":"IC Fontana","year":"2023","unstructured":"Fontana IC, Kumar A, Nordberg A. The role of astrocytic \u03b17 nicotinic acetylcholine receptors in Alzheimer disease. Nat Rev Neurol. 2023;19:278\u201388.","journal-title":"Nat Rev Neurol"},{"key":"3418_CR18","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/alz.12787","volume":"19","author":"A Pichet Binette","year":"2023","unstructured":"Pichet Binette A, Janelidze S, Cullen N, Dage JL, Bateman RJ, Zetterberg H, et al. Confounding factors of Alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance. Alzheimer\u2019s Dement. 2023;19:1403\u201314.","journal-title":"Alzheimer\u2019s Dement"},{"key":"3418_CR19","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","volume":"12","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Janelidze S, Al Khleifat A, Leuzy A, van der Ende EL, Karikari TK, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun. 2021;12:3400.","journal-title":"Nat Commun"},{"key":"3418_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.35068","volume":"5","author":"I Hajjar","year":"2022","unstructured":"Hajjar I, Yang Z, Okafor M, Liu C, Waligorska T, Goldstein FC, et al. Association of plasma and cerebrospinal fluid Alzheimer disease biomarkers with race and the role of genetic ancestry, vascular comorbidities, and neighborhood factors. JAMA Netw Open. 2022;5: e2235068.","journal-title":"JAMA Netw Open"},{"key":"3418_CR21","doi-asserted-by":"publisher","first-page":"e473","DOI":"10.1212\/WNL.0000000000201479","volume":"100","author":"V Planche","year":"2023","unstructured":"Planche V, Bouteloup V, Pellegrin I, Mangin J-F, Dubois B, Ousset P-J, et al. Validity and performance of blood biomarkers for Alzheimer disease to predict dementia risk in a large clinic-based cohort. Neurology. 2023;100:e473\u201384.","journal-title":"Neurology"},{"key":"3418_CR22","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1212\/WNL.0000000000207193","volume":"101","author":"D Alcolea","year":"2023","unstructured":"Alcolea D, Beeri MS, Rojas JC, Gardner RC, Lle\u00f3 A. Blood biomarkers in neurodegenerative diseases: implications for the clinical neurologist. Neurology. 2023;101:172\u201380.","journal-title":"Neurology"},{"key":"3418_CR23","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/s41590-023-01588-w","volume":"24","author":"JH Zhao","year":"2023","unstructured":"Zhao JH, Stacey D, Eriksson N, Macdonald-Dunlop E, Hedman \u00c5K, Kalnapenkis A, et al. Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets. Nat Immunol. 2023;24:1540\u201351.","journal-title":"Nat Immunol"},{"key":"3418_CR24","unstructured":"UK Biobank Team. UKB \u2013 Olink Explore 1536 - Data Normalization Strategy. https:\/\/biobank.ndph.ox.ac.uk\/showcase\/refer.cgi?id=4656. Accessed 19 Jun 2023."},{"key":"3418_CR25","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41562-023-01585-x","volume":"7","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Chen S-D, Deng Y-T, You J, He X-Y, Wu X-R, et al. Identifying modifiable factors and their joint effect on dementia risk in the UK Biobank. Nat Hum Behav. 2023;7:1185\u201395.","journal-title":"Nat Hum Behav"},{"key":"3418_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.18314","volume":"5","author":"KA Duchowny","year":"2022","unstructured":"Duchowny KA, Ackley SF, Brenowitz WD, Wang J, Zimmerman SC, Caunca MR, et al. Associations between handgrip strength and dementia risk, cognition, and neuroimaging outcomes in the UK Biobank cohort study. JAMA Netw Open. 2022;5: e2218314.","journal-title":"JAMA Netw Open"},{"key":"3418_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231627","volume":"15","author":"C Fawns-Ritchie","year":"2020","unstructured":"Fawns-Ritchie C, Deary IJ. Reliability and validity of the UK Biobank cognitive tests. PLoS ONE. 2020;15: e0231627.","journal-title":"PLoS ONE"},{"key":"3418_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154222","volume":"11","author":"DM Lyall","year":"2016","unstructured":"Lyall DM, Cullen B, Allerhand M, Smith DJ, Mackay D, Evans J, et al. Cognitive test scores in UK Biobank: data reduction in 480,416 participants and longitudinal stability in 20,346 participants. PLoS ONE. 2016;11: e0154222.","journal-title":"PLoS ONE"},{"key":"3418_CR29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12882-022-02750-6","volume":"23","author":"EL Richard","year":"2022","unstructured":"Richard EL, McEvoy LK, Deary IJ, Davies G, Cao SY, Oren E, et al. Markers of kidney function, genetic variation related to cognitive function, and cognitive performance in the UK Biobank. BMC Nephrol. 2022;23:159.","journal-title":"BMC Nephrol"},{"key":"3418_CR30","unstructured":"UK Biobank Team. UKB - Category 100026 - Cognitive function. https:\/\/biobank.ndph.ox.ac.uk\/showcase\/label.cgi?id=100026. Accessed 19 Jun 2023."},{"key":"3418_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j2709","volume":"357","author":"S Sabia","year":"2017","unstructured":"Sabia S, Dugravot A, Dartigues J-F, Abell J, Elbaz A, Kivim\u00e4ki M, et al. Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study. BMJ. 2017;357: j2709.","journal-title":"BMJ"},{"key":"3418_CR32","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ana.25910","volume":"89","author":"Y Leng","year":"2021","unstructured":"Leng Y, Ackley SF, Glymour MM, Yaffe K, Brenowitz WD. Genetic risk of Alzheimer\u2019s disease and sleep duration in non-demented elders. Ann Neurol. 2021;89:177\u201381.","journal-title":"Ann Neurol"},{"key":"3418_CR33","doi-asserted-by":"crossref","unstructured":"Van Diepen M, Ramspek CL, Jager KJ, Zoccali C, Dekker FW. Prediction versus aetiology: common pitfalls and how to avoid them. Nephrology Dialysis Transplantation. 2017;32 suppl_2:ii1\u20135.","DOI":"10.1093\/ndt\/gfw459"},{"key":"3418_CR34","doi-asserted-by":"publisher","first-page":"7817","DOI":"10.1038\/s41467-023-43575-7","volume":"14","author":"J You","year":"2023","unstructured":"You J, Guo Y, Zhang Y, Kang J-J, Wang L-B, Feng J-F, et al. Plasma proteomic profiles predict individual future health risk. Nat Commun. 2023;14:7817.","journal-title":"Nat Commun"},{"key":"3418_CR35","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1474-4422(06)70537-3","volume":"5","author":"M Kivipelto","year":"2006","unstructured":"Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol. 2006;5:735\u201341.","journal-title":"Lancet Neurol"},{"key":"3418_CR36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12916-016-0549-y","volume":"14","author":"K Walters","year":"2016","unstructured":"Walters K, Hardoon S, Petersen I, Iliffe S, Omar RZ, Nazareth I, et al. Predicting dementia risk in primary care: development and validation of the Dementia Risk Score using routinely collected data. BMC Med. 2016;14:6.","journal-title":"BMC Med"},{"key":"3418_CR37","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","volume":"21","author":"EW Steyerberg","year":"2010","unstructured":"Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21:128\u201338.","journal-title":"Epidemiology"},{"key":"3418_CR38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/brain\/awad374","volume":"147","author":"V Grut","year":"2024","unstructured":"Grut V, Bistr\u00f6m M, Salzer J, Stridh P, Jons D, Gustafsson R, et al. Human herpesvirus 6A and axonal injury before the clinical onset of multiple sclerosis. Brain. 2024;147:177\u201385.","journal-title":"Brain"},{"key":"3418_CR39","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/clinchem\/hvad018","volume":"69","author":"X-N Shen","year":"2023","unstructured":"Shen X-N, Huang S-Y, Cui M, Zhao Q-H, Guo Y, Huang Y-Y, et al. Plasma glial fibrillary acidic protein in the Alzheimer Disease Continuum: relationship to other biomarkers, differential diagnosis, and prediction of clinical progression. Clin Chem. 2023;69:411\u201321.","journal-title":"Clin Chem"},{"key":"3418_CR40","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/s41591-023-02380-x","volume":"29","author":"B Bellaver","year":"2023","unstructured":"Bellaver B, Povala G, Ferreira PCL, Ferrari-Souza JP, Leffa DT, Lussier FZ, et al. Astrocyte reactivity influences amyloid-\u03b2 effects on tau pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2023;29:1775\u201381.","journal-title":"Nat Med"},{"key":"3418_CR41","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/acn3.51670","volume":"9","author":"AJ Aschenbrenner","year":"2022","unstructured":"Aschenbrenner AJ, Li Y, Henson RL, Volluz K, Hassenstab J, Verghese P, et al. Comparison of plasma and CSF biomarkers in predicting cognitive decline. Ann Clin Transl Neurol. 2022;9:1739\u201351.","journal-title":"Ann Clin Transl Neurol"},{"key":"3418_CR42","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","volume":"76","author":"N Mattsson","year":"2019","unstructured":"Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2019;76:791\u20139.","journal-title":"JAMA Neurol"},{"key":"3418_CR43","doi-asserted-by":"crossref","unstructured":"Heimfarth L, Passos FRS, Monteiro BS, Ara\u00fajo AA de S, Quintans J\u00fanior LJ, Quintans J de SS. Serum glial fibrillary acidic protein is a body fluid biomarker: a valuable prognostic for neurological disease - a systematic review. Int Immunopharmacol. 2022;107:108624.","DOI":"10.1016\/j.intimp.2022.108624"},{"key":"3418_CR44","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","volume":"18","author":"A Abdelhak","year":"2022","unstructured":"Abdelhak A, Foschi M, Abu-Rumeileh S, Yue JK, D\u2019Anna L, Huss A, et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. 2022;18:158\u201372.","journal-title":"Nat Rev Neurol"},{"key":"3418_CR45","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.scib.2023.07.009","volume":"68","author":"F Gao","year":"2023","unstructured":"Gao F, Dai L, Wang Q, Liu C, Deng K, Cheng Z, et al. Blood-based biomarkers for Alzheimer\u2019s disease: a multicenter-based cross-sectional and longitudinal study in China. Sci Bull. 2023;68:1800\u20138.","journal-title":"Sci Bull"},{"key":"3418_CR46","doi-asserted-by":"publisher","first-page":"e874","DOI":"10.1212\/WNL.0000000000201289","volume":"100","author":"KB Rajan","year":"2023","unstructured":"Rajan KB, McAninch EA, Aggarwal NT, Barnes LL, Wilson RS, Weuve J, et al. Longitudinal changes in blood biomarkers of clinical Alzheimer disease in a biracial population sample. Neurology. 2023;100:e874\u201383.","journal-title":"Neurology"},{"key":"3418_CR47","doi-asserted-by":"publisher","first-page":"e860","DOI":"10.1212\/WNL.0000000000201597","volume":"100","author":"J Sarto","year":"2023","unstructured":"Sarto J, Ruiz-Garc\u00eda R, Guill\u00e9n N, Ramos-Campoy \u00d3, Falg\u00e0s N, Esteller D, et al. Diagnostic Performance and clinical applicability of blood-based biomarkers in a prospective memory clinic cohort. Neurology. 2023;100:e860\u201373.","journal-title":"Neurology"},{"key":"3418_CR48","first-page":"43","volume":"15","author":"M Nasb","year":"2024","unstructured":"Nasb M, Tao W, Chen N. Alzheimer\u2019s disease puzzle: delving into pathogenesis hypotheses. Aging Dis. 2024;15:43\u201373.","journal-title":"Aging Dis"},{"key":"3418_CR49","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Smith R, Mattsson-Carlgren N, Palmqvist S, Teunissen CE, et al. Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease. Brain. 2021;144:3505\u201316.","journal-title":"Brain"},{"key":"3418_CR50","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41588-022-01024-z","volume":"54","author":"C Bellenguez","year":"2022","unstructured":"Bellenguez C, K\u00fc\u00e7\u00fckali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al. New insights into the genetic etiology of Alzheimer\u2019s disease and related dementias. Nat Genet. 2022;54:412\u201336.","journal-title":"Nat Genet"},{"key":"3418_CR51","doi-asserted-by":"crossref","unstructured":"Coppola G, Chinnathambi S, Lee JJ, Dombroski BA, Baker MC, Soto-Ortolaza AI, et al. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer\u2019s diseases. Hum Mol Genet. 2012;21:3500\u201312.","DOI":"10.1093\/hmg\/dds161"},{"key":"3418_CR52","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/aps.2017.28","volume":"38","author":"G-F Chen","year":"2017","unstructured":"Chen G-F, Xu T-H, Yan Y, Zhou Y-R, Jiang Y, Melcher K, et al. Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin. 2017;38:1205\u201335.","journal-title":"Acta Pharmacol Sin"},{"key":"3418_CR53","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13195-023-01277-8","volume":"15","author":"H Stocker","year":"2023","unstructured":"Stocker H, Trares K, Beyer L, Perna L, Rujescu D, Holleczek B, et al. Alzheimer\u2019s polygenic risk scores, APOE, Alzheimer\u2019s disease risk, and dementia-related blood biomarker levels in a population-based cohort study followed over 17 years. Alz Res Therapy. 2023;15:129.","journal-title":"Alz Res Therapy"},{"key":"3418_CR54","doi-asserted-by":"crossref","unstructured":"Bradley J, Gorijala P, Schindler SE, Sung YJ, Ances B, the Alzheimer\u2019s disease neuroimaging initiative, the human connectome project, et al. Genetic architecture of plasma Alzheimer disease biomarkers. Human Molecular Genetics. 2023;32:2532\u201343.","DOI":"10.1093\/hmg\/ddad087"},{"key":"3418_CR55","doi-asserted-by":"crossref","unstructured":"Ramanan VK, Gebre RK, Graff-Radford J, Hofrenning E, Algeciras-Schimnich A, Figdore DJ, et al. Genetic risk scores enhance the diagnostic value of plasma biomarkers of brain amyloidosis. Brain. 2023;:awad196.","DOI":"10.1093\/brain\/awad196"},{"key":"3418_CR56","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/gerona\/glab030","volume":"76","author":"I Skoog","year":"2021","unstructured":"Skoog I, Kern S, Najar J, Guerreiro R, Bras J, Waern M, et al. A Non-APOE polygenic risk score for Alzheimer\u2019s disease is associated with cerebrospinal fluid neurofilament light in a representative sample of cognitively unimpaired 70-year-olds. J Gerontol A Biol Sci Med Sci. 2021;76:983\u201390.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"3418_CR57","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1016\/S2666-7568(20)30061-1","volume":"2","author":"IMW Verberk","year":"2021","unstructured":"Verberk IMW, Laarhuis MB, van den Bosch KA, Ebenau JL, van Leeuwenstijn M, Prins ND, et al. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. Lancet Healthy Longev. 2021;2:e87-95.","journal-title":"Lancet Healthy Longev"},{"key":"3418_CR58","doi-asserted-by":"publisher","first-page":"e661","DOI":"10.1016\/S2468-2667(20)30185-7","volume":"5","author":"L Jia","year":"2020","unstructured":"Jia L, Du Y, Chu L, Zhang Z, Li F, Lyu D, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. Lancet Public Health. 2020;5:e661\u201371.","journal-title":"Lancet Public Health"},{"key":"3418_CR59","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.1002\/alz.13373","volume":"19","author":"EM Litkowski","year":"2023","unstructured":"Litkowski EM, Logue MW, Zhang R, Charest BR, Lange EM, Hokanson JE, et al. Mendelian randomization study of diabetes and dementia in the Million Veteran Program. Alzheimer\u2019s Dement. 2023;19:4367\u201376.","journal-title":"Alzheimer\u2019s Dement"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03418-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-024-03418-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03418-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T20:02:25Z","timestamp":1715544145000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-024-03418-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3418"],"URL":"https:\/\/doi.org\/10.1186\/s12916-024-03418-8","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,13]]},"assertion":[{"value":"4 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the NHS National Research Ethics Service (16\/NW\/0274) and informed consent was obtained from each participant before data collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"192"}}